Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Johnson_&_Johnson
|
| gptkbp:acquisitionYear |
1961
|
| gptkbp:CEO |
gptkb:Jennifer_Taubert
|
| gptkbp:developedVaccine |
gptkb:Janssen_COVID-19_vaccine
|
| gptkbp:focusArea |
immunology
infectious diseases neuroscience oncology cardiovascular and metabolic diseases |
| gptkbp:foundedBy |
gptkb:Paul_Janssen
|
| gptkbp:foundedIn |
1953
|
| gptkbp:headquartersLocation |
gptkb:Beerse,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Janssen
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Risperdal
gptkb:Spravato gptkb:Imbruvica gptkb:Darzalex gptkb:Stelara |
| gptkbp:parentCompany |
gptkb:Johnson_&_Johnson
|
| gptkbp:website |
https://www.janssen.com/
|
| gptkbp:bfsParent |
gptkb:Jansen
gptkb:erythropoietin |
| gptkbp:bfsLayer |
6
|